公开(公告)号：US20200281964A1

公开(公告)日：2020-09-10

申请号：US16788909

申请日：2020-02-12

申请人： Balakrishnan Siddartha Ramakrishna ,  Yale University ,  Flinders University of South Australia

发明人： Balakrishnan Siddartha Ramakrishna ,  Graeme Paul Young ,  Ian Lewis Brown ,  Henry Joseph Binder

IPC分类号： A61K33/00 ,  A23L2/38 ,  A61K31/718 ,  A61K33/14 ,  A61K47/36 ,  A61K9/00 ,  A23L2/52 ,  A61K33/30 ,  A61K33/34 ,  A61K33/06 ,  A23L33/105 ,  A23L33/16 ,  A23L29/212 ,  A23L33/10 ,  A23L33/21 ,  A23L29/269 ,  A23L29/238 ,  A23L29/256 ,  A23L29/231 ,  A23L29/25 ,  A23L29/281 ,  A61K31/194 ,  A61K31/7004

摘要： Provided herein are compositions, for example: oral rehydration compositions, beverages, food items, methods and uses, which utilise resistant starch to prevent or treat dehydration, including dehydration which is caused by diarrhoea. Beverages, food items and oral rehydration solutions including a resistant starch, which are suitable for aiding in the maintenance and restoration of hydration levels in individuals undertaking physical activities, including sports, are also disclosed.

公开(公告)号：US20200268787A1

公开(公告)日：2020-08-27

申请号：US16866366

申请日：2020-05-04

申请人： THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

发明人： George B. Stefano ,  Richard M. Kream ,  Kirk J. Mantione

IPC分类号： A61K31/718 ,  A61K36/81 ,  A61K9/00 ,  A61K9/08 ,  A61P25/28 ,  A61K9/20 ,  A61K31/355 ,  A61K31/385

摘要： This document provides methods and materials for reducing amyloid beta levels within a mammal (e.g. a mammal having Alzheimer's disease). For example, this document provides methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of Alzheimer's disease. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to increase binding, sequestration, and/or degradation of CNS-derived amyloid beta polypeptides, thereby inhibiting the formation of neurofibrillary plaques.

公开(公告)号：US20200164019A1

公开(公告)日：2020-05-28

申请号：US16632953

申请日：2018-07-17

申请人： SAMI LABS LIMITED

发明人： Muhammed Majeed ,  Kaiyanam Nagabhushanam ,  Beena Bhat ,  Natarajan Sankaran

IPC分类号： A61K36/9066 ,  A61P29/00 ,  A61K31/718 ,  A61P19/02 ,  C07K14/415 ,  C08B30/20

摘要： The present invention relates to a process for the isolation of bioactive components from spent turmeric (Curcuma longa) and compositions comprising said bioactive components. Further, the present invention also elucidates the potent anti-inflammatory activity of said bioactive compositions and therapeutic applications thereof in rheumatoid arthritis.

公开(公告)号：US20190336573A1

公开(公告)日：2019-11-07

申请号：US16401698

申请日：2019-05-02

申请人： Seattle Children's Hospital (d/b/a Seattle Children's Research Institute)

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61K9/00 ,  C07K16/06 ,  C07K16/24 ,  A61K31/047 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K31/25 ,  A61K31/05 ,  A61K47/18 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61K31/60 ,  A61K31/192 ,  A61P17/00

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.

公开(公告)号：US20190330333A1

公开(公告)日：2019-10-31

申请号：US16471718

申请日：2017-12-26

申请人： Kao Corporation

发明人： Fumiaki OKAHARA ,  Yoshitaka KOGA ,  Takuya MORI

IPC分类号： C07K16/26 ,  A61K31/166 ,  A61K31/404 ,  A61K36/07 ,  A61K31/519 ,  A61K31/734 ,  A61K31/683 ,  A61K31/785 ,  A61K36/185 ,  A61K31/717 ,  A61K31/722 ,  A61K31/718 ,  A61K31/215 ,  A61K31/201

摘要： Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.

公开(公告)号：US10441602B2

公开(公告)日：2019-10-15

申请号：US15288533

申请日：2016-10-07

申请人： MICROBIOME THERAPEUTICS LLC

发明人： Mark L. Heiman ,  Dean P. Stull ,  Justin W. Peno

IPC分类号： A61K36/00 ,  A61K31/733 ,  A61K31/047 ,  A61K31/716 ,  A61K31/718 ,  A61K36/45 ,  A61K9/00 ,  A61K31/155 ,  A61K38/28 ,  A23L29/212 ,  A23L33/00 ,  A23L33/105 ,  A23L33/21 ,  A61K31/05 ,  A61K36/88 ,  A61K36/899 ,  A61K9/10

摘要： A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.

公开(公告)号：US20190262382A1

公开(公告)日：2019-08-29

申请号：US16271089

申请日：2019-02-08

申请人： McPharma Biotech Inc.

发明人： Derek McLaren ,  Earl McLaren

IPC分类号： A61K31/718 ,  A61P1/14 ,  A61P1/04 ,  A61P1/06 ,  A61P1/12

摘要： Resistant potato starch is demonstrated to have therapeutic effects on ulcerative colitis through attenuation of diarrhea, repair or reduction of intestinal damage, modulation of local gene expression and treatment of intestinal dysbiosis. Administering resistant potato starch in pigs pre-exposed to colitis improved fecal score although use of resistant potato starch as a preventive measure did not prevent diarrhea associated with induction of colitis and in fact impaired the ability of the resistant potato starch to treat ulcerative colitis.

公开(公告)号：US10391105B2

公开(公告)日：2019-08-27

申请号：US15700314

申请日：2017-09-11

申请人： Marinus Pharmaceuticals Inc.

发明人： Christopher Cashman ,  Jaakko Lappalainen ,  David A Czekai

IPC分类号： A61K31/56 ,  A61K31/573 ,  C07J7/00 ,  A61K31/721 ,  A61K31/718

摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.

公开(公告)号：US20180333429A1

公开(公告)日：2018-11-22

申请号：US15596372

申请日：2017-05-16

申请人： Medical Symbiosis Pty Ltd

发明人： David Reiner

IPC分类号： A61K31/718 ,  A61K9/00 ,  A23L2/60

CPC分类号： A61K31/718 ,  A23L2/60 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0095

摘要： The present invention relates to a fasting formulation and a method of use that assists a patient during a fasting period and to reduce side effects of the fasting. Furthermore, the invention promotes better recovery from fasting. The formulation contains maltodextrin and is devoid of simple sugars. The invention further relates to the use of the formulation as a pre-operative for preparing for surgery and anaesthesia using the formulation.

公开(公告)号：US10010563B2

公开(公告)日：2018-07-03

申请号：US14435362

申请日：2012-11-27

申请人： TERUMO KABUSHIKI KAISHA

发明人： Hirokazu Usami ,  Yoshihiko Koyama ,  Hiroshi Nishitani ,  Tsuyoshi Ariizumi

IPC分类号： A61M1/00 ,  A61K33/14 ,  A61K31/718 ,  A61M1/28 ,  A61J1/10 ,  A61J1/20

CPC分类号： A61K33/14 ,  A61J1/10 ,  A61J1/202 ,  A61J1/2093 ,  A61K31/718 ,  A61M1/287 ,  A61K2300/00

摘要： The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing 60.0 to 94.0 g/L of icodextrin and 0 to 2.34 g/L of sodium chloride, and an alkaline second liquid containing an alkaline pH regulator, in which the first liquid after sterilization has a pH of 5.0 to 5.5, the second liquid after sterilization has a pH of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a pH of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the pH of the peritoneal dialysis fluid is close to the physiological range.